PHS
CHRS icon

PFM Health Sciences’s Coherus Oncology CHRS Stock Holding History

PFM Health Sciences’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-411,727
Closed -$7.35M – 80
2020
Q2 		$7.35M Sell
411,727
-62,328
-13% -$1.05M 0.38% 68
2020
Q1 		$7.69M Sell
474,055
-61,031
-11% -$1.13M 0.63% 48
2019
Q4 		$9.63M Sell
535,086
-154,739
-22% -$2.85M 0.46% 49
2019
Q3 		$14M Sell
689,825
-768,160
-53% -$15.3M 0.41% 54
2019
Q2 		$32.2M Buy
1,457,985
+510,924
+54% +$8.87M 0.61% 55
2019
Q1 		$12.9M Buy
+947,061
New +$12.6M 0.29% 74
2017
Q3 		– Sell
-1,802,611
Closed -$25.9M – 96
2017
Q2 		$25.9M Buy
1,802,611
+302,929
+20% +$5.83M 0.7% 50
2017
Q1 		$31.7M Buy
+1,499,682
New +$36.9M 0.79% 52
2016
Q1 		– Sell
-172,638
Closed -$3.96M – 84
2015
Q4 		$3.96M Sell
172,638
-122,941
-42% -$3.16M 0.12% 62
2015
Q3 		$5.92M Buy
295,579
+7,500
+3% +$228K 0.17% 59
2015
Q2 		$8.32M Buy
+288,079
New +$7.28M 0.21% 69

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

PFM Health Sciences's CHRS Position: Q3 2020 in Review

PFM Health Sciences sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 411,727 shares — an estimated $7.35M sold.

PFM Health Sciences first reported a position in CHRS in Q2 2015 and held it in 11 quarters. The position peaked at $32.2M in Q2 2019. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

  • PFM Health Sciences reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
  • PFM Health Sciences sold 411,727 Coherus Oncology shares in Q3 2020, an estimated $7.35M.
  • PFM Health Sciences first reported a position in Coherus Oncology in Q2 2015 and held it in 11 quarters.
  • PFM Health Sciences's Coherus Oncology position peaked at $32.2M in Q2 2019.
  • 201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on PFM Health Sciences's 13F filing for Q3 2020, filed 16 Nov 2020.